News
SCNX
0.4497
-4.68%
-0.0221
Weekly Report: what happened at SCNX last week (0810-0814)?
Weekly Report · 5d ago
Analyst Maintains Buy Rating and $1.50 Price Target on Scienture Amid Strong Early Commercialization for Arbli and Rezenopy
TipRanks · 08/15 17:15
Scienture Holdings Q2 non-GAAP EPS of -$0.07, revenue of $0.34M
Seeking Alpha · 08/14 15:47
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Benzinga · 08/14 12:23
*Scienture Holdings 2Q Loss/Shr 7c >SCNX
Dow Jones · 08/14 12:09
*Scienture Holdings 2Q Rev $343,639 >SCNX
Dow Jones · 08/14 12:09
Scienture Holdings: Q2 Earnings Snapshot
Barchart · 08/13 17:37
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
Benzinga · 08/12 11:46
Weekly Report: what happened at SCNX last week (0803-0807)?
Weekly Report · 08/10 09:32
Weekly Report: what happened at SCNX last week (0727-0731)?
Weekly Report · 08/03 09:32
Weekly Report: what happened at SCNX last week (0720-0724)?
Weekly Report · 07/27 09:34
Weekly Report: what happened at SCNX last week (0713-0717)?
Weekly Report · 07/20 09:32
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 07/13 12:05
Weekly Report: what happened at SCNX last week (0706-0710)?
Weekly Report · 07/13 09:33
Analysts Are Bullish on Top Healthcare Stocks: Scienture Holdings (SCNX), Royalty Pharma (RPRX)
TipRanks · 07/10 15:10
Why WD-40 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 07/10 08:45
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why
Benzinga · 07/10 08:27
Scienture Announces Commercial Inventory Readiness For REZENOPY Naloxone Nasal Spray; Stock Up
NASDAQ · 07/10 06:10
Scienture to begin shipments of Rezonopy to wholesalers
TipRanks · 07/09 13:35
Scienture To Begin Shiptments Of REZENOPY Nasal Spray 10mg To U.S. Pharmaceutical Wholesalers Later This Month
Benzinga · 07/09 12:14
More
Webull provides a variety of real-time SCNX stock news. You can receive the latest news about Scienture Holdings, Inc through multiple platforms. This information may help you make smarter investment decisions.
About SCNX
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.